fbpx
Connect with us

News

Ultromics aims to revolutionise cardiac disease treatment

Avatar photo

Published

on

Ultromics aims to revolutionise cardiac disease treatment

Health tech firm Ultromics has raised £24m to speed the progress of its AI-based cardiovascular imaging solution.

The firm, headquartered in Oxford, UK, aims to use the funds to accelerate its AI-enabled echocardiograms.

CEO and co-founder Dr. Ross Upton said: “Echocardiograms uploaded to the cloud and analysed by artificial intelligence are set to revolutionise cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy.

“This funding [will] allow Ultromics to dramatically accelerate the use of AI-enhanced Echo into studies that currently use more expensive and less accurate imaging techniques.”  

Founded in 2017, Ultromics’ EchoGo Core and EchoGo Pro platforms quickly deliver accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis.

Both were spun out of the University of Oxford and built-in partnership with the NHS.

Its funding round was led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation.

Oxford Sciences Innovation aims to help scientific breakthroughs become world-changing businesses and supported Ultromics in getting off the ground.

EchoGo Core and EchoGo Pro are already being used and validated by several organisations, including Mayo Clinic and the Oregon Health and Science University, both in the US.

EchoGo Core recently featured in a study which showed Ultromics’ AI-generated echocardiography analysis could provide meaningful predictors of health outcomes, where manual analysis did not.

Dr. Emir Sandhu, MD of the Blue Venture Fund, said: “Cardiovascular disease is the leading cause of morbidity and mortality in the United States, and Ultromics offers groundbreaking AI solutions for more accurate diagnosis. We are excited to partner with Dr. Ross Upton and the Ultromics’ team, as they promote improved patient outcomes.”

Dr. Vijay Barathan, Optum Ventures said: “Ultromics’ software significantly improves the ability of clinicians to leverage low-cost ultrasound imaging to address cardiovascular disease, one of the greatest healthcare burdens of our generation. We are thrilled to be supporting the Ultromics team in their mission to improve patient lives through AI enabled cardiovascular imaging solutions.”

 

Continue Reading
1 Comment

1 Comment

  1. Pingback: How “humanised” mouse model could advance organ transplants

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories